The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pabst, O.
Right arrow Articles by Förster, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pabst, O.
Right arrow Articles by Förster, R.
The Journal of Immunology, 2006, 176: 1474-1480.
Copyright © 2006 by The American Association of Immunologists

Enhanced FTY720-Mediated Lymphocyte Homing Requires G{alpha}i Signaling and Depends on beta2 and beta7 Integrin1

Oliver Pabst*, Heike Herbrand*, Stefanie Willenzon*, Tim Worbs*, Angela Schippers{dagger}, Werner Müller{dagger}, Günter Bernhardt* and Reinhold Förster2,*

* Institute of Immunology, Hannover Medical School, Hannover, Germany; and {dagger} Department of Experimental Immunology, Gesellschaft für Biologische Forschung, Braunschweig, Germany

The immunomodulatory drug FTY720 interferes with sphingosine-1-phosphate (S1P) receptor signaling leading to lymphocyte retention in secondary lymphoid organs and consequently to profound lymphopenia in the peripheral blood. The molecular mechanisms transduced by S1P receptors upon being triggered by its native ligand, S1P, or by FTY720, are largely unknown. In this study we analyze the role of beta2 and beta7 integrin and their ligands ICAM-1, VCAM-1, and MadCAM-1 on lymphocyte homing in the presence of FTY720. We demonstrate that this drug facilitates homing of lymphocytes single-deficient of either beta2 or beta7 integrin but not of beta2-deficient lymphocytes, which in addition were blocked by anti-beta7 integrin Abs. Enhanced lymphocyte homing is preceded by increased adherence of integrin-deficient as well as wild-type lymphocytes to high endothelial venules (HEV) in FTY720-treated animals. Elevated adherence to HEV requires intact lymphocyte G{alpha}i signaling that cannot be stably imprinted on lymphocytes even after prolonged exposure to FTY720. Thus, FTY720 influences lymphocyte homeostasis not only by suppressing lymphocyte egress from lymph nodes but also by facilitating lymphocyte homing across HEV in an integrin-dependent fashion.




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
S.-C. Sensken, C. Bode, and M. H. Graler
Accumulation of Fingolimod (FTY720) in Lymphoid Tissues Contributes to Prolonged Efficacy
J. Pharmacol. Exp. Ther., March 1, 2009; 328(3): 963 - 969.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
N. Czeloth, A. Schippers, N. Wagner, W. Muller, B. Kuster, G. Bernhardt, and R. Forster
Sphingosine-1 Phosphate Signaling Regulates Positioning of Dendritic Cells within the Spleen
J. Immunol., November 1, 2007; 179(9): 5855 - 5863.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Jennrich, B. A. Ratsch, A. Hamann, and U. Syrbe
Long-Term Commitment to Inflammation-Seeking Homing in CD4+ Effector Cells
J. Immunol., June 15, 2007; 178(12): 8073 - 8080.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
O. Pabst, H. Herbrand, M. Friedrichsen, S. Velaga, M. Dorsch, G. Berhardt, T. Worbs, A. J. Macpherson, and R. Forster
Adaptation of Solitary Intestinal Lymphoid Tissue in Response to Microbiota and Chemokine Receptor CCR7 Signaling
J. Immunol., November 15, 2006; 177(10): 6824 - 6832.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2006 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2006 by The American Association of Immunologists, Inc. All rights reserved.